Die FDA bietet keinen selbst aktualisierenden News-Dienst an, Informationen über aktuelle FDA-Zulassungen können auf der FDA-Homepage eingesehen werden.

Der kommerzielle Anbieter drugs.com publiziert einen Nachrichtendienst mit Informationen zu allen Neuzulassungen der FDA.

• Octapharma USA Announces Expanded FDA Approval of wilate for von Willebrand Disease Prophylaxis in Children Younger Than 6 Years
  08.07.2026
  PARAMUS, N.J., July 8, 2026 /PRNewswire/ — On July 2, 2026, the U.S. Food and Drug Administration (FDA) approved the use of wilate® (von Willebrand […]
• FDA Grants Accelerated Approval for Trutakna (atacicept-vymj) for Adult Patients with Primary IgA Nephropathy
  08.07.2026
  BRISBANE, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug […]
• Vertex Announces FDA Approval for Expanded Use of Casgevy for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
  02.07.2026
  BOSTON–(BUSINESS WIRE)–Jul. 1, 2026– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of Casgevy […]
• FDA Approves Tregzi (Orca-T) as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies
  30.06.2026
  MENLO PARK, CA, June 30, 2026 – Orca Bio, a commercial-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today […]
• FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
  29.06.2026
  WESTLAKE VILLAGE, Calif., June 29, 2026 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, […]